We developed a novel complex made from therapeutic oligonucleotide CpG ODN and natural beta-glucan. When we applied this complex with influenza vaccine, immune stimulation due to the vaccine was dramatically increased for mice and monkey. This complex played a role of adjuvant and this technology can be used for a wide variety of field.
Research Area : “Development of the foundation for nano-interface technology”
Research Theme : “Manipulation of nano interface of drug-delivery system and its application to vaccine for bird flu”
Published in “Proceedings of the National Academy of Sciences of the United States of America”
Kouji Kobiyamaa, Taiki Aoshi, Hirotaka Naritac, Etsushi Kurodab, Masayuki Hayashi, Kohhei Tetsutani, Shohei Koyamad, Shinichi Mochizuki, Kazuo Sakurai, Yuko Katakai, Yasuhiro Yasutomi,
Shinobu Saijoi, Yoichiro Iwakura, Shizuo Akira, Cevayir Coban, and Ken J. Ishii
“Nonagonistic Dectin-1 ligand transforms CpG into a multitask nanoparticlulate TLR9 agonist”
Ken Ishii, M.D., Ph.D.
Project Leader, Laboratory of Adjuvant Innovation, National Institute of Biomedical Innovation
Kazuo Sakurai Ph.D.
Professor, Faculty of Environmental Engineering, The University of Kitakyushu
Green Innovation Group, Department of Innovation Research, Japan Science and Technology Agency